Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Healthcare spending in the U.S. is rising, benefiting companies like Aveanna Healthcare Holdings, which focuses on home-based ...

The three groups preparing to bid are Lone Star and Kenedix, Bain and Tokyu Fudosan, and KKR, PAG and Nomura Real Estate, two ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Bain Capital and KKR are among three groups preparing bids for Sapporo Holdings' real estate business, valued at approximately $2.7 billion. Sapporo is selling its real estate hol ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...